TSHA vs VSTM: fair value comparison
Taysha Gene Therapies, Inc. and Verastem, Inc. · Updated 2026-10-19
TSHA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. VSTM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TSHA currently ranks higher by quality score.
| TSHA | VSTM | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $3.62 | $8.65 |
| 12-month range | $3.51–$6.98 | $3.45–$10.64 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #273 of 301 Healthcare | #275 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | High |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: TSHA fair value analysis · VSTM fair value analysis